Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
ActiveMax® Recombinant Human Oncostatin M (OSM) protein, 50µg  

ActiveMax® Recombinant Human Oncostatin M (OSM) protein, 50µg

ActiveMax® Recombinant Human Oncostatin M (OSM) Ala 26 - Arg 252 was produced in human 293 cells (HEK293), Tag free

Synonym: Recombinant Human Protein, OSM,MGC20461,Oncostatin M

More details

OSM-H5213-50

Availability: within 7 days

540,00 €

Background
Oncostatin M is also known as OSM, is a glycoprotein belonging to the interleukin-6 family of cytokines that has functions mainly in cell growth. Of these cytokines it most closely resembles leukemia inhibitory factor (LIF) in both structure and function. However, it is as yet poorly defined and is proving important in liver development, haematopoeisis, inflammation and possibly CNS development. It is also associated with bone formation and destruction. OSM signals through cell surface receptors that contain the protein gp130. The type I receptor is composed of gp130 and LIFR, the type II receptor is composed of gp130 and OSMR. Oncostatin M (OSM) was previoustly identified by its ability to inhibit the growth of cells from melanoma and other solid tumors. It also has been reported that OSM, like LIF, IL-6 and G-CSF, has the ability to inhibit the proliferation of murine M1 myeloid leukemic cells and can induce their differentiation into macrophage-like cells. The human form of OSM is insensitive between pH2 and 11 and resistant to heating for one hour at 56 degree but is not stable at 90 degrees. The three dimensional structure of human OSM has been solved to atomic resolution, confirming the predicted long chain four helix bundle topology. Comparing this structure with the known structures of other known LC cytokines shows it to be most closely related to LIF.

Source
ActiveMax® Recombinant Human Oncostatin M (OSM) (ActiveMax® Human Oncostatin M) Ala 26 - Arg 252 (Accession # NP_065391.1) was produced in human 293 cells (HEK293).

Molecular Characterization
ActiveMax® Human Oncostatin M contains no "tag", and has a calculated MW of 25.8 kDa. The predicted N-terminus is Ala 26. DTT-reduced Protein migrates as 36 kDa in SDS-PAGE due to glycosylation.

Endotoxin
Less than 1.0 EU per μg of the ActiveMax® Human Oncostatin M by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C); After reconstitution under sterile conditions for 3 months (-70°C).
 
Bioactivity
Please refer to product data sheet.

References

(1) Tanaka M, Miyajima A., 2003, Reviews of Physiology, Biochemistry and Pharmacology 149: 39–52.
(2) Walker EC, et al., 2010, J Clin Invest 120 (2): 582–92.
(3) Auguste P, et al., 1997, J. Biol. Chem. 272 (25): 15760–4.
(4) Deller MC, et al., 1997, Structure 8 (8): 863–74.